GANGLOFF ANTHONY R
No ORCID on file
· 48 papers in corpus
· active 2002-2007
Frequent coauthors
- RICE Kenneth D. 48
- STEIN Bernd M. 48
- CHAO QI 48
- BHAGWAT Shripad S. 48
- MCKIE Jeffrey A. 48
- GAYO-FUNG LEAH MARIE 24
- GAYO-FUNG Leah M. 24
2007
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-beta over ER-alpha. Methods are disclosed for modulat…
2007
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-beta over ER-alpha. Methods are disclosed for modulat…
2007
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-beta over ER-alpha. Methods are disclosed for modulat…
2007
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-beta over ER-alpha. Methods are disclosed for modulat…
2007
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-beta over ER-alpha. Methods are disclosed for modulat…
2007
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-beta over ER-alpha. Methods are disclosed for modulat…
2007
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-beta over ER-alpha. Methods are disclosed for modulat…
2007
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-beta over ER-alpha. Methods are disclosed for modulat…
2004
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-beta over ER-alpha. Methods are disclosed for modulat…
2004
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-beta over ER-alpha. Methods are disclosed for modulat…
2004
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-beta over ER-alpha. Methods are disclosed for modulat…
2004
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-beta over ER-alpha. Methods are disclosed for modulat…
2004
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-beta over ER-alpha. Methods are disclosed for modulat…
2004
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-beta over ER-alpha. Methods are disclosed for modulat…
2004
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-beta over ER-alpha. Methods are disclosed for modulat…
2004
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-beta over ER-alpha. Methods are disclosed for modulat…
2003
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-beta over ER-alpha. Methods are disclosed for modu…
2003
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-beta over ER-alpha. Methods are disclosed for modu…
2003
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-beta over ER-alpha. Methods are disclosed for modu…
2003
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-beta over ER-alpha. Methods are disclosed for modu…
2003
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-beta over ER-alpha. Methods are disclosed for modu…
2003
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-beta over ER-alpha. Methods are disclosed for modu…
2003
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-beta over ER-alpha. Methods are disclosed for modu…
2003
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-beta over ER-alpha. Methods are disclosed for modu…
2003
Compounds have the structure: including srereoisomers and pharmaceutically acceptable salts thereof; wherein a is 0, 1 or 2; A, B and C are independently CH, CR or N, wherein R is C1-6 alkyl; D is-(CH2)nC(=O)(CH2)m-; R1, R2, R3 are substitu…